Delivering the promise of the decade of vaccines: Opportunities and challenges in the development of high quality new vaccines

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Keith, Jacqueline A ^a   Agostini Bigger, Laetitia ^b   Arthur, Phyllis A ^c   Maes, Edith ^d,e   Daems, Rutger ^e  

^a Strategy XXI Partners   (United States)

^b International Federation of Pharmaceutical Manufacturers and Associations   (Switzerland)

^c Biotechnology Industry Organization   (United States)

^d MAASTRICHT SCHOOL OF MANAGEMENT   (Netherlands)

^e Planet Strategy Group   (Belgium)

Author keywords

Differential pricing; Innovative vaccines; National prioritization of immunization; Public private partnerships; Research push pull mechanisms; Uniform high quality standards

Indexed keywords

VACCINE;

DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH PROGRAM; IMMUNIZATION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW;

BIOMEDICAL RESEARCH; DRUG INDUSTRY; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; VACCINES;

EID: 84876727509     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.032     Document Type: Review

References (34)

1. Global Vaccine Action Plan. Vaccine 2013, 31:B5-B31. Decade of Vaccines Collaboration.
2. Sachdev H., Hall A., Walker N. Development and use of the lives saved tool (LiST): a model to estimate the impact of scaling up proven interventions on maternal, neonatal, and child mortality. Int J Epidemiol 2010, 39(April (Suppl. 1)).
3. Bill and Melinda Gates Foundation Global health leaders launch Decade of Vaccines collaboration December 2, 2010.
4. Krause R. The value of vaccines: two centuries of unparalleled medical progress 2008, International Federation of Pharmaceutical Companies and Associations (IFPMA), Geneva, Switzerland.
5. WHO position paper on human papillomavirus vaccines. Wkly Epidemiol Rec 2009, 84(15):117-132.
6. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3):S11-S25.
7. WHO position paper on meningococcal vaccines. Wkly Epidemiol Rec 2011, 86(47):521-540.
8. WHO position paper on pneumococcal vaccines Wkly Epidemiol Rec 2012, 87(14):129-144.
9. WHO position paper on rotavirus vaccines. Wkly Epidemiol Rec 2009, 84(51-52):533-540.
10. WHO position paper on varicella vaccines. Wkly Epidemiol Rec 1998, 73:241-248.
11. BIO Ventures for Global Health Developing new drugs & vaccines for neglected diseases of the poor March 2012, The Product Developer Landscape.
12. Vaccines in Development, PhRMA 2012 Report.
13. Grace C. Product development partnerships (PDP): lessons from PDPs established to develop new health technologies for neglected diseases 2010, DFID, London, England.
14. Andre F., Bogaerts H. Vaccinology in principles and practice of clinical virology 2009, John Wiley & Sons Ltd. 6th ed. A. Zuckerman, J. Banatvala, B. Schoub, P. Griffiths, P. Mortimer (Eds.).
15. Joint Position on the Publication of Clinical Trial Results in the Scientific Literature, EFPIA, IFPMA, JPMA, PhRMA (announced 10 June 2010), . http://clinicaltrials.ifpma.org/clinicaltrials/fileadmin/files/pdfs/20100610_Joint_Position_Publication_10Jun2010.pdf.
16. Levine H. Vaccine manufacturing facilities of the future December 1-2, 2010, BioProcess Technology Consultants, London, England.
17. The biomedical research & development guide 2006, Biomedical Industry Advisory Group.
18. Struck M.M. Vaccine research and product development success rates and development times. Nat Biotechnol 1996, 14:591-593.
19. Andre F.E. How the research-based industry approaches vaccine development and established priorities. Dev Biol (Basel) 2002, 110:25-29.
20. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715.
21. Dimasi J., Hansen R., Grabowski H. The price of innovation; new estimates of drug development costs. J Health Econ 2003, 22(151):185.
22. Gapper J. Pharma needs an injection of financial engineering. Financial Times May 3, 2012.
23. World Intellectual Property Organization (WIPO) WIPO Re:Search - sharing innovation in the fight against neglected tropical diseases 2012, WIPO, Geneva, Switzerland. http://www.wiporesearch.org/.
24. Bloom D., Canning D., Weston M. The value of vaccination. World Econ 2005, 6(July-September (3)).
25. Bregu M., Draper S., Hill A., Greenwood B. Accelerating vaccine development and deployment: report of A Royal Society Satellite Meeting. Philos. Trans. R. Soc. B 2011, 366:2841-2849. 10.1098/rstb.2011.0100.
26. Larson H., Cooper L., Eskola J., Katz S., Ratzan S. Addressing the vaccine confidence gap. Lancet 2011, [Epub ahead of print]. 10.1016/S0140-6736(11)60678-8.
27. Wilson P. Giving developing countries the best shot: an overview of vaccine access and R&D 2010, Campaign for Access to Essential Medicines; Médecins Sans Frontières, Geneva, Switzerland.
28. Lob-Levyt J. Contribution of the GAVI Alliance to improving health and reducing poverty. Philos. Trans. R. Soc. 2011, 366:2743-2747.
29. GAVI Alliance Progress report 2011 2012, GAVI Alliance, Geneva, Switzerland.
30. Makinen M. Synthesis report: new vaccine adoption in lower-middle-income countries 2011, The Results for Development Institute, Washington, DC.
31. Milstein J. Regulation of vaccines: strengthening the science base. Health 2004, 25(2):173-189.
32. GAVI Alliance draft Report to the Programme and Policy Committee, April 23-24, 2012. Programme Update: Market Shaping.
33. Hecht R., Wilson P., Palriwala A. Improving health R&D financing for developing countries: a menu of innovative policy options. Health Aff 2009, 28(July (4)):974-985.
34. Trotsenburg A. Pilot advance market commitment for pneumococcal diseases. World Vaccine Congress 2012.